Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Aptose Biosciences Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
0
0
Research and development
7.83
6.27
18.7
16.8
29.3
46
24.5
33.3
15.1
11.3
General and administrative
5.55
10.4
10
26.5
19.5
14.5
15.6
11.2
13.4
Operating expenses
11.8
29.1
26.9
55.8
65.4
42.6
52.4
26.3
24.7
Interest expense
0.05
Interest income
0.08
0.07
0.28
0.57
0.52
0.09
0.79
1.15
0.36
0.11
Other non-operating income
0.18
0.24
0.58
0.53
0.09
0.78
1.15
0.83
-0.75
Pre-tax income
-7.81
-21.8
-20.5
-39.8
-52.4
-36.6
-45.7
-21.6
-20.9
Income tax
0
0
Net income
-14.2
-11.6
-28.9
-26.3
-55.2
-65.4
-41.8
-51.2
-25.4
-25.5
EPS, basic
-506.87
-235.33
-389.20
-235.33
-303.22
-330.37
-204.03
-227.43
-36.38
-10.41
EPS, diluted
-506.87
-235.33
-389.20
-235.33
-303.22
-330.37
-204.03
-227.43
-36.38
-10.41
Shares, basic (weighted)
0.05
0.07
0.11
0.18
0
0.21
0.23
0.7
2.45
Shares, diluted (weighted)
0.05
0.07
0.11
0.18
0
0.21
0.23
0.7
2.45
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
7.94
10.6
15.3
79.8
117
39.1
37
9.25
6.15
0.94
Short-term investments
0.8
0.44
17.8
5
40
9.99
Other current assets
0.07
0.1
0.14
0.13
0.13
0.26
0.6
0.57
0.14
Total current assets
8.43
11.8
16.5
98.8
125
81.7
49.5
11.9
9.53
6.45
Property, plant and equipment
0.21
0.14
0.38
0.33
0.26
0.32
0.21
0.15
0.03
0
Lease right-of-use assets
1.38
0.93
0.47
1.3
0.94
0.57
0.18
Other non-current assets
0
3.39
Total assets
8.65
12
16.9
100
126
82.5
51
13
10.1
10
Accounts payable
1.32
0.59
1.32
1.96
2.17
1.7
3.34
3.49
1.26
2.91
Accrued liabilities
1.18
1.47
3.06
4.1
6.02
5.09
8.83
2.77
6.2
Total current liabilities
1.32
1.77
2.79
5.54
6.81
8.17
12.3
15.3
4.46
9.31
Lease liabilities
1.01
0.54
0.12
1
0.62
0.19
0
Total liabilities
1.32
1.77
2.79
6.55
7.35
8.29
13.3
15.9
14.7
37.2
Paid-in capital
29.4
33
34.6
50.9
63.7
68.9
72.1
83.3
83.8
Retained earnings
-235
-247
-276
-302
-357
-423
-464
-516
-541
-566
Other comprehensive income
-4.32
-4.32
-4.3
-4.32
-4.32
-4.32
-4.32
-4.32
-4.32
Shareholders' equity
7.33
10.2
14.1
93.9
119
74.2
37.7
-2.9
-4.54
-27.2
Total equity
7.33
10.2
14.1
93.9
119
74.2
37.7
-2.9
-4.54
-27.2
Total liabilities and equity
8.65
12
16.9
100
126
82.5
51
13
10.1
10
Shares outstanding
0.06
0.08
0.17
0.2
0.2
0.21
0.26
2.01
2.55
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-14.2
-11.6
-28.9
-26.3
-55.2
-65.4
-41.8
-51.2
-25.4
-25.5
Depreciation and amortization
0.08
0.09
0.15
0.15
0.15
0.12
0.09
0.03
0.02
Stock-based compensation
0.82
4.28
2.3
21.4
12.9
5.21
3.65
1.06
0.48
Change in payables
0.59
0.73
0.65
0.21
-0.47
4.63
Cash from operations
-12.4
-10.2
-23.2
-21.6
-33.9
-43.3
-32.3
-44.6
-36
-22
Capital expenditures
-0
-0.01
-0.33
-0.1
-0.08
-0.21
-0.02
-0.03
-0.01
0
Sales and maturities of investments
9.99
0
Cash from investing
6.48
-0.81
0.01
-17.4
12.6
-35.2
30.1
9.96
0.02
0
Stock issued
5.73
13.4
0.24
0.72
0.57
0.19
0.02
0
Cash from financing
5.73
13.7
27.9
103
58.8
0.23
0.12
6.91
33.4
19.4
Exchange rate effect
-0.18
0.01
-0.01
0.02
0.01
0.01
Net change in cash
-0.37
2.69
4.67
64.5
37.6
-78.3
-2.14
-27.7
-2.55
-2.61
Free cash flow
-12.4
-10.2
-23.5
-21.7
-34
-43.5
-32.3
-44.6
-36
-22
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. No valuation: we have no share price for this company.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-257.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-1.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-41.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-39.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
250.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
128.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
68.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.55x
Current assets / current liabilities.
Quick ratio
0.09x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.09x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$9.81
Cash from operations / diluted weighted shares.
Book value per share
-$13.58
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
What was Aptose Biosciences Inc.'s revenue in fiscal 2025?
Aptose Biosciences Inc. reported revenue of $0.0 for fiscal 2025.
Was Aptose Biosciences Inc. profitable in fiscal 2025?
No. It reported a net loss of $25.5M.
How much free cash flow did Aptose Biosciences Inc. generate in fiscal 2025?
Cash from operations of $22.0M minus capital expenditures of $0.0 left free cash flow of -$22.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.